United States - English - NLM (National Library of Medicine)

elanco us inc. - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) - robenacoxib 10 mg - onsior should not be used in dogs that have a hypersensitivity to robenacoxib or known intolerance to nsaids.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) -

United States - English - NLM (National Library of Medicine)

novartis animal health us, inc. - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) - robenacoxib 6 mg

United States - English - NLM (National Library of Medicine)

novartis animal health us, inc. - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) - robenacoxib 20 mg in 1 ml

United States - English - NLM (National Library of Medicine)

elanco us inc. - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) - onsior (robenacoxib) injection should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to nsaids. (6 mg tablets) and subcutaneously (20 mg/ml solution) to 4-month old cats at 0, 1, and 5 times the labeled doses (1x = 2.4 mg/kg/day orally based on the inherent tablet dose band or 2.0 mg/kg/day subcutaneously). interchangeable use was evaluated by alternating three 7-day oral tablet/3-day subcutaneous injection cycles followed by one final 7-day oral tablet dosing cycle. clinical findings included: scabs and sores at the injection sites of one 1x female and two 5x females, and injection site edema noted more frequently in treated cats. injection site changes were characterized as minimal to moderate granulomatous inflammation, minimal to moderate fibroplasia/fibrosis, and minimal myofiber regeneration of the panniculus carnosus. in one 1x female, moderate necrosis of a blood vessel was noted within the granulomatous inflammation. minimal myofiber regeneration was observed in

United States - English - NLM (National Library of Medicine)

elanco us inc. - robenacoxib (unii: z588009c7c) (robenacoxib - unii:z588009c7c) - onsior tablets should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to nsaids. onsior was administered orally (6 mg tablets) and subcutaneously (20 mg/ml solution) to 4-month old healthy cats at 0, 1, 2, and 3 times the labeled doses (1x = 2.4 mg/kg/day orally based on the inherent tablet dose band or 2.0 mg/kg/day subcutaneously). interchangeable use was evaluated by alternating three 7-day oral tablet/3-day subcutaneous injection cycles followed by one final 7-day oral tablet dosing cycle. all cats survived until study termination. findings included: elevated creatine kinase levels on days 13 and 37, soft stools, histologic observation of a minimal oral (tongue) ulceration in a 1x cat, injection site edema for up to 120 hours prior to resolution, and a prolonged qt interval in treated cats as compared to the controls on day 36. there was a dose dependent and statistically significant increase in the qt interval at all three onsior tablets/onsior injection treatment le

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - robenacoxib - unknown - robenacoxib anti-inflammatory-non-steroida active 0.0 - active constituent

European Union - English - EMA (European Medicines Agency)

elanco gmbh - robenacoxib - anti-inflammatory and anti-rheumatic products, non-steroids, coxibs - dogs; cats - cats (tablets):for the treatmentrelief of pain and inflammation associated with acute andor chronic musculo-skeletal disorders.for the reduction of moderate pain and inflammation associated with orthopaedic surgery.dogs (tablets):for the ttreatment of pain and inflammation associated with chronic osteoarthritis.for the treatment of pain and inflammation associated with soft tissue surgery.cats and dogs (solution for injection):for the ttreatment of pain and inflammation associated with orthopaedic or soft tissue surgery.

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - robenacoxib - chewable tablet - robenacoxib

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - robenacoxib - chewable tablet - robenacoxib